Mesoblast posts quarterly revenue uptick from Ryoncil sales
Make us a preferred source
Make us a preferred source on Google
The news: Biotech company Mesoblast said net revenue from its cell therapy Ryoncil reached USD115 million ($166 million) for the year ending 30 June, as quarterly sales edged up.
The numbers: Mesoblast reported Ryoncil net revenue of USD36 million for the June quarter, up from USD30 million in the March quarter.
Shares in the company were up 0.2% to $2.11 at 10:55am AEST. The stock is down around 23% since January.
The context: Melbourne-based Mesoblast first launched its Roncil therapy in the US in March 2025. It is the first FDA-approved therapy for children aged two months and older with steroid-refractory acute graft versus host disease, a life-threatening condition with high mortality rates that can arise from an allogeneic bone marrow transplant.
What they said: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major US pediatric centers,” said Mesoblast CEO Silviu Itescu.
“Our capital position is strong, operation activities are well funded through revenue growth, and the new five-year facility has freed up our label extension and blockbuster products for strategic initiatives.”
The source: ASX
